Updates are available Correction dated 2024-09-23
Click to view Correction: https://doi.org/10.1038/s41586-024-08068-7
-
Authors
Nomburg, Jason https://orcid.org/0000-0001-7807-8658
Doherty, Erin E. https://orcid.org/0000-0002-1555-4124
Price, Nathan https://orcid.org/0000-0002-7008-4620
Bellieny-Rabelo, Daniel https://orcid.org/0000-0003-2544-7899
Zhu, Yong K.
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 10 July 2024
First Online: 26 August 2024
Change Date: 23 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-08068-7
Competing interests
: The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. and J.N. are listed as inventors on a patent filing related to DNA-binding proteins characterized in this work. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Evercrisp, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, The Column Group and Inari. She also is an advisor for Aditum Bio. J.A.D. is Chief Science Advisor to Sixth Street, a Director at Johnson & Johnson, Altos and Tempus, and has research projects sponsored by Apple Tree Partners. The other authors declare no competing interests.
